Ahmedabad: Zydus Lifesciences Limited has announced that it has received in principle acceptability from World Health Organisation (WHO) for ZyVac TCV. ZyVac TCV is now eligible for purchase by United Nations (UN) agencies. ZyVac TCV is indigenously developed and manufactured at the Zydus Biotech Park, Ahmedabad.

Zydus Lifesciences' shares rose 2.81% after receiving WHO approval for its indigenously developed typhoid vaccine, ZyVac TCV, making it eligible for UN agency procurement. .

Indian multinational pharmaceutical company Zydus Lifesciences Ltd on Wednesday announced that its Typhoid Vi conjugate vaccine, ZyVac TCV, has received in-principle approval from the World Health Organization (WHO), paving the way for the vaccine to be eligible for purchase by United Nations (UN) procurement agencies.

Zydus Lifesciences' ZyVac TCV typhoid vaccine receives WHO prequalification, opening doors for UN procurement programs in high-risk regions.

As per GAVI (2022) it is estimated that Typhoid accounts for an estimated 11 to 21 million cases of febrile illness and 117,000 to 161,000 deaths are attributed to the disease each year.

Zydus Lifesciences' ZyVac TCV receives WHO prequalification, eligible for U.N. procurement, combating typhoid fever in high-risk regions.